Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
925 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03173560 | Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | completed | Phase 2 | 343 | Eisai Inc.INDUSTRY | 16 | Apr 1, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT02423603 | PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer(PAKT) | completed | Phase 2 | 71 | Queen Mary University of LondonOTHER | 6 | Mar 10, 2025 | clinicaltrials |
| NCT06867172 | Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma(SPACE) | recruiting | — | 66 | Carol Davila University of Medicine and PharmacyOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer(RESILIENT) | completed | Phase 3 | 491 | IpsenINDUSTRY | 18 | Feb 19, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT00753545 | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | completed | Phase 2 | 265 | AstraZenecaINDUSTRY | 17 | Feb 3, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT05085977 | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)(ADVANCED-1) | completed | Phase 1 | 12 | Protara TherapeuticsINDUSTRY | 4 | Jan 27, 2025 | clinicaltrials |
| NCT02240238 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | completed | Phase 1 / Phase 2 | 119 | NanoCarrier Co., Ltd.INDUSTRY | 5 | Jan 22, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY | 25 | Dec 18, 2024 | clinicaltrials |
| NCT02754882 | A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 763 | Samsung Bioepis Co., Ltd.INDUSTRY | 13 | Dec 16, 2024 | clinicaltrials |
| NCT03673306 | Safety of Pregnancy in BRCA Mutated Breast Cancer Patients | completed | — | 4,732 | Jules Bordet InstituteOTHER | 26 | Dec 13, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY | 23 | Dec 10, 2024 | clinicaltrials |
| NCT01288911 | A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | completed | Phase 2 | 375 | Astellas Pharma IncINDUSTRY | 8 | Dec 6, 2024 | clinicaltrials |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | active not recruiting | Phase 3 | 531 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Dec 3, 2024 | clinicaltrials |
| NCT02216786 | A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer(MANTA) | completed | Phase 2 | 333 | Queen Mary University of LondonOTHER | 9 | Dec 2, 2024 | clinicaltrials |
| NCT05396807 | REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients(REVERT) | completed | N/A | 106 | University of Rome Tor VergataOTHER | 3 | Nov 29, 2024 | clinicaltrials |
| NCT02927262 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | completed | Phase 2 | 98 | Astellas Pharma Global Development, Inc.INDUSTRY | 21 | Nov 26, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer(PEACE1) | active not recruiting | Phase 3 | 1,173 | UNICANCEROTHER | 7 | Nov 12, 2024 | clinicaltrials |
| NCT06033976 | Endoscopic Submucosal Dissection Registry(ESDREG) | recruiting | — | 200 | Carol Davila University of Medicine and PharmacyOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT03189719 | First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) | completed | Phase 3 | 749 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Oct 15, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT04428333 | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(INDUCE-4) | terminated | Phase 3 | 117 | GlaxoSmithKlineINDUSTRY | 19 | Oct 9, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT01285557 | Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial(DIGEST) | terminated | Phase 3 | 361 | Taiho Oncology, Inc.INDUSTRY | 20 | Sep 19, 2024 | clinicaltrials |
| NCT02500043 | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | completed | Phase 3 | 507 | Taiho Oncology, Inc.INDUSTRY | 18 | Sep 3, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
| NCT03668119 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)(CheckMate 848) | completed | Phase 2 | 212 | Bristol-Myers SquibbINDUSTRY | 17 | Aug 28, 2024 | clinicaltrials |
| NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | completed | Phase 3 | 815 | Astex Pharmaceuticals, Inc.INDUSTRY | 24 | Aug 27, 2024 | clinicaltrials |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma(BOSTON) | completed | Phase 3 | 402 | Karyopharm Therapeutics IncINDUSTRY | 21 | Aug 21, 2024 | clinicaltrials |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients(OPINION) | completed | Phase 3 | 279 | AstraZenecaINDUSTRY | 19 | Aug 21, 2024 | clinicaltrials |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer(IMpassion030) | terminated | Phase 3 | 2,199 | Hoffmann-La RocheINDUSTRY | 31 | Aug 21, 2024 | clinicaltrials |
| NCT05947903 | Validation of the European Oncology Quality of Life Toolkit | unknown | — | 4,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 32 | Aug 20, 2024 | clinicaltrials |
| NCT03859427 | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma(ARROW2) | completed | Phase 3 | 454 | AmgenINDUSTRY | 17 | Aug 13, 2024 | clinicaltrials |
| NCT02668653 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)(QuANTUM-First) | completed | Phase 3 | 539 | Daiichi SankyoINDUSTRY | 28 | Aug 6, 2024 | clinicaltrials |
| NCT03306394 | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).(PRECONNECT) | completed | Phase 3 | 907 | Institut de Recherches Internationales ServierOTHER | 16 | Jul 25, 2024 | clinicaltrials |
| NCT06512142 | Using Artificial Intelligence for the Detection of Respiratory Diseases Associated With Pollution(SmartLungs) | unknown | — | 30,000 | University of Medicine and Pharmacy "Victor Babes" TimisoaraOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas(GAMMA) | completed | Phase 3 | 800 | NantCell, Inc.INDUSTRY | 32 | Jul 16, 2024 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials